Core Points - The CEO of Alstom, Henri Poupart-Lafarge, has decided not to seek a fourth term, with his current term ending at the General Meeting for the financial year ending March 31, 2027 [1] - The Board of Directors is initiating the process to identify a successor to ensure a smooth transition [1] - The Board expressed satisfaction with the annual results published on May 14, highlighting the effectiveness of Poupart-Lafarge's management [2] - Poupart-Lafarge will continue as CEO until a successor is appointed [2] Company Overview - Alstom is committed to a low carbon future by developing sustainable transportation solutions, including high-speed trains, metros, and digital mobility services [3] - The company operates in 63 countries and employs over 86,000 people from 184 nationalities [3] - For the fiscal year ending March 31, 2025, Alstom generated sales of €18.5 billion [3]

Core Points - An Extraordinary General Meeting (EGM) of Prosafe SE was held virtually on 16 May 2025 [1] - All proposals on the agenda were adopted as per the notice published on 25 April 2025 [1] - Minutes from the EGM are available for download from specified links [1] Company Information - The EGM was conducted via Lumi platform [1] - Contact information for CEO Terje Askvig and CFO Reese McNeel is provided for further inquiries [1] - The information is disclosed in accordance with the Norwegian Securities Trading Act [1]

Core Insights - Mainz Biomed N.V. plans to provide an interim readout of its eAArly DETECT 2 feasibility study by the end of summer 2025, with top-line results expected in Q4 2025 [1][2] - The study aims to validate a next-generation colorectal cancer screening test that combines proprietary mRNA biomarkers, an AI-developed algorithm, and a FIT test on approximately 2,000 average-risk patients [1][3] - The company is on track to initiate its U.S. pivotal trial, ReconAAsense, in 2026 based on the outcomes of the eAArly DETECT 2 study [2][3] Study Details - The eAArly DETECT 2 study is expected to complete enrollment in the second half of 2025, targeting the reporting of top-line results by Q4 2025 [2] - The study will evaluate the effectiveness of five novel mRNA biomarkers acquired from Sherbrooke University in 2022, which have shown the ability to identify advanced adenomas and early-stage colorectal cancer [3] Company Mission - The company aims to advance its mission of eliminating colorectal cancer and reducing global cancer mortality rates through precise detection of advanced precancerous lesions and early-stage colorectal cancer [3]

WARRINGTON, Pa., May 16, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the first quarter ended March 31, 2025 and provided key business updates. “The first quarter of 2025 was marked with significant progress. We announced our new corporate strategy to become a reve ...

Company Urges Stockholders to Vote ‘FOR’ Reverse Stock Split Proposal at Upcoming Annual Meeting to Avoid Nasdaq Delisting Leading Independent Proxy Advisory Firms, ISS and Glass Lewis, Support Proposal #2 SOUTH SAN FRANCISCO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has filed a supplement to its proxy statement for its Annual Meeting. The board of directors approved the following two items, if Proposal #2 passes: The current authorized number of shares of ...

TORONTO, May 16, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that management will participate in a fireside chat at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, on Tuesday, May 20, 2025 at 11:30 a.m. ET at the Nasdaq headquarters in New York City, New York. Investors interested in scheduling a meeting with the Company's management team sho ...

New system utilizes advancements in physical AI to provide customers efficient and precise artisanal coffee products Las Vegas, NV, May 16, 2025 (GLOBE NEWSWIRE) -- Richtech Robotics Inc. (Nasdaq: RR) (“Richtech Robotics” or the “Company”), a Nevada-based provider of AI-driven service robots, is expanding the capabilities of its AI-powered barista robot, ADAM, with a new artisanal espresso system debuting at the National Restaurant Association Show at McCormick Place Convention Center in Chicago from May 17 ...

Company in Advanced Discussions to Restructure Convertible Debt and Unlock Shareholder ValuePotential Agreement Expected to Improve Financial Flexibility and Reduce Dilution Pressure WEST PALM BEACH, FL, May 16, 2025 (GLOBE NEWSWIRE) -- QHSLab Inc. (the “Company”) (OTCQB: USAQ), a digital health company advancing personalized medicine through innovative population health screening and point of care diagnostic tools in primary care, today announced that it is in advanced discussions with Catheter Precision, ...

TORONTO, May 16, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on ketamine for unmet medical needs, today announced the U.S. Food and Drug Administration (FDA) has extended the approval goal date for the review of its new drug application for ketamine. The new approval goal date is August 9, 2025, revised from the previous date of June 4, 2025. The extension allows the FDA additional time to review add ...

Core Viewpoint - NowVertical Group Inc. is set to announce its Q1 2025 financial results on May 21, 2025, followed by a webinar to discuss these results and provide a business outlook [1][2]. Company Overview - NowVertical Group Inc. is a global data and analytics company that specializes in transforming data into business value using AI technologies. The company offers a comprehensive suite of solutions and services aimed at helping clients optimize decision-making, improve operational efficiency, and unlock long-term value from their data [4]. Upcoming Events - The Q1 2025 financial results will be discussed in a webinar scheduled for May 22, 2025, at 10:00 AM EST, featuring key executives including the CEO and Interim CFO [2][3]. - A live question-and-answer session will follow the presentation during the webinar [2]. Registration and Access - Interested participants can register for the webinar through a provided link, and a recording along with supporting materials will be available on the company's investor relations website [3].